EQ001 Placebo

BIOLOGICAL4 trials

Sponsors

Equillium, Biocon Limited

Conditions

Acute GVHDAcute-graft-versus-host DiseaseAsthmaCoronavirusGVHDGVHD, AcuteGraft Versus Host DiseaseaGVHD

Phase 1

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

CompletedNCT03763318

EquilliumAcute-graft-versus-host Disease, aGVHD, GVHD +1

Start: 2019-07-15End: 2022-11-21Updated: 2025-04-18

A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma

CompletedNCT04007198

EquilliumAsthma

Start: 2019-06-20End: 2021-10-12Updated: 2025-04-18

Phase 3

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

WithdrawnNCT04605926

Biocon LimitedCoronavirus

Start: 2020-11-01End: 2021-06-01Updated: 2026-05-12

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

TerminatedNCT05263999

EquilliumAcute-graft-versus-host Disease, Acute GVHD, aGVHD +2

Start: 2022-04-29End: 2025-05-12Updated: 2025-06-17

Related Papers

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

Blood2025-11-031 citations

PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

HemaSphere2022-06-012 citations

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation

Haematologica2022-04-2815 citations

Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease

Blood2021-11-053 citations

Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab

Blood2020-11-041 citations

Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease

Blood2019-11-135 citations

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Blood2019-11-132 citations

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood2019-11-132 citations